Breaking News Instant updates and real-time market news.

PYPL

PayPal

$106.94

2.92 (2.81%)

, ATVI

Activision Blizzard

$56.18

1.28 (2.33%)

10:17
09/12/19
09/12
10:17
09/12/19
10:17

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) assumed at Buy, up from Hold at Canaccord with analyst Joseph Vafi saying PayPal is a "payments juggernaut," and its growth in payment volumes "at this scale is impressive." 2. Activision Blizzard (ATVI) upgraded to Buy from Neutral at Nomura Instinet with analyst Andrew Marok saying last month's launch of World of Warcraft Classic has driven "strong, above-expectations" engagement in the franchise. 3. Voya Financial (VOYA) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Alex Scott saying Voya has a better ability to beat earnings estimates in the near term as well as in 2020 and 2021 relative to Prudential Financial (PRU). 4. AbbVie (ABBV) upgraded to Buy from Neutral at UBS with analyst Navin Jacob saying he sees the company's acquisition of Allegan as "highly compelling," with NewCo generating over $20B of annual free cash flow and a 9% yield by 2023 when its Humira exclusivity patent expires. 5. Kaman (KAMN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Steve Barger citing meetings with management. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

PYPL

PayPal

$106.94

2.92 (2.81%)

ATVI

Activision Blizzard

$56.18

1.28 (2.33%)

VOYA

Voya Financial

$53.10

-0.19 (-0.36%)

ABBV

AbbVie

$70.37

0.72 (1.03%)

KAMN

Kaman

$64.01

1.88 (3.03%)

  • 12

    Sep

  • 16

    Sep

  • 27

    Sep

PYPL PayPal
$106.94

2.92 (2.81%)

09/11/19
ADAM
09/11/19
UPGRADE
ADAM
Buy
PayPal assumed at Buy, up from Hold at Canaccord
Canaccord analyst Joseph Vafi assumed coverage of PayPal with a Buy rating, up from the firm's prior Hold rating.
09/05/19
JEFF
09/05/19
DOWNGRADE
Target $32
JEFF
Hold
Jefferies downgrades Green Dot to Hold, cuts target to $32 from $62
Jefferies analyst John Hecht downgraded Green Dot (GDOT) to Hold from Buy and lowered his price target for the shares to $32 from $62. The company's organic revenue growth has been slowing and it is trying to establish share in a new customer target market with well-resourced competitors, Hecht tells investors in a research note. In addition, Green Dot's current new customer goals "look like a stretch in light of historical trends," adds the analyst. He points out that Square (SQ) and PayPal (PYPL) are observing monthly downloads at a rate of six-times Green Dot. Hecht sees potential downside to earnings and few positive catalysts in the intermediate term for Green Dot.
09/03/19
ATLE
09/03/19
INITIATION
Target $50
ATLE
Underweight
Atlantic Equities starts Square with Underweight rating, $55 price target
Atlantic Equities analyst Kunaal Malde initiated coverage of Square (SQ) with an Underweight rating and $55 price target. The shares closed Friday at $61.84. Square's core business is decelerating and the mix shift to consumer payments increases uncertainty, Malde tells investors in a research note. The company's core merchant acquiring yields are too high versus peers that are increasingly competing with combined hardware/software platforms, adds the analyst. Further, he points out that PayPal's (PYPL) Venmo is regaining ground on Square's Cash App. Malde this morning also initiated coverage of FIS (FIS) with an Overweight rating as well as Fiserv (FISV) and Jack Henry (JKHY) with Neutral ratings.
09/11/19
ADAM
09/11/19
UPGRADE
Target $118
ADAM
Buy
Canaccord assumes 'payments juggernaut' PayPal at Buy, up from Hold
Canaccord Genuity analyst Joseph Vafi assumed coverage of PayPal and upgraded the shares to Buy from Hold with a price target of $118, up from $110. PayPal is a "payments juggernaut," and its growth in payment volumes "at this scale is impressive," Vafi tells investors in a research note. The analyst sees a positive risk/reward following the recent pullback in the shares.
ATVI Activision Blizzard
$56.18

1.28 (2.33%)

09/09/19
STFL
09/09/19
NO CHANGE
Target $65
STFL
Buy
Stifel adds Activision Blizzard to Select List, boosts price target to $65
Stifel analyst Drew Crum added Activision Blizzard to his firm's Select List and boosted his price target for the shares to $65 from $57. The stock closed Friday at $54.58. The analyst sees possible upside for Call of Duty: Modern Warfare, which launches on October 25, as he believes expectations "have been generally lower." Further, BlizzCon 2019 could serve as a share catalyst while Activision's fundamentals should improve in 2020 against an easy comp, Crum tells investors in a research note. He keeps a Buy rating on the shares.
09/05/19
09/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comcast (CMCSA) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company's fundamentals are "healthy" in the near-term, and 2020 is setting up to be a "strong year." 2. Activision Blizzard (ATVI) upgraded to Overweight from Equal Weight at Stephens with analyst Jeff Cohen citing his view that estimates for 2019 are now "de-risked" due to the successful launch of World of Warcraft Classic and the announcement of a Nintendo Switch port of Overwatch. 3. Match Group (MTCH) upgraded to Buy from Hold at SunTrust with analyst Youssef Squali saying that the "positive" intra-quarter app traffic and revenue trends imply a positive quarter-to-date momentum for the company. 4. Incyte (INCY) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Perform at Oppenheimer. 5. National Oilwell (NOV) upgraded to Buy from Hold at Jefferies with analyst Bradley Handler saying even with the uncertain macro environment, National Oilwell's outlook includes backlog-based growth potential and less margin risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/19
NOMU
09/12/19
UPGRADE
Target $64
NOMU
Buy
Activision Blizzard upgraded to Buy from Neutral at Nomura Instinet
Nomura Instinet analyst Andrew Marok upgraded Activision Blizzard to Buy from Neutral and raised his price target for the shares to $64 from $49. The game maker closed yesterday down $1.12 to $54.91. Last month's launch of World of Warcraft Classic has driven "strong, above-expectations" engagement in the franchise, Marok tells investors in a research note. Further, Overwatch has recently added new features and last week announced a launch on the Nintendo Switch, the analyst points out. He believes these provides a "much more favorable backdrop" heading into November's BlizzCon, where he expects Activision will see the reveal of a World of Warcraft expansion for 2020 release and at least one of Diablo 4 or Overwatch 2.
09/12/19
JEFF
09/12/19
NO CHANGE
JEFF
Jefferies says stick with Activision Blizzard after video game survey
After surveying 600 U.S. video game players to gauge interest in the fall content slate and track overall engagement trends, Jefferies analyst Alex Giaimo tells investors to stick with his top pick Activision Blizzard (ATVI). Survey takeaways were positive for the upcoming Call of Duty: Modern Warfare 4, with 36% of responders planning to buy the game, says the analyst. He remains selective and favors Activision over Electronic Arts (EA) and Take-Two Interactive (TTWO).
VOYA Voya Financial
$53.10

-0.19 (-0.36%)

07/12/19
SBSH
07/12/19
NO CHANGE
SBSH
Citi opens 'Negative Catalyst Watches' on MetLife and Prudential
Citi analyst Suneet Kamath opened "Negative Catalyst Watches" on both MetLife (MET) and Prudential (PRU). He believes 2020 consensus estimates look too high for Sell-rated MetLife. On Buy-rated Prudential, the analyst believes the company's Q2 assumption review could drive a charge in Individual Life and lower the segment's run-rate earnings power. Kamath favors "equity sensitive names" and stocks at "below average" valuation multiples into the Q2 earnings season, namely Ameriprise (AMP), Lincoln National (LNC) and Voya Financial (VOYA).
08/07/19
MSCO
08/07/19
NO CHANGE
Target $64
MSCO
Overweight
Voya target lowered to $64 at Morgan Stanley after 'somewhat disappointing' Q2
Morgan Stanley analyst Nigel Dally said he viewed Voya Financial's second quarter as "somewhat disappointing" after the company had been on a run of delivering strong EPS growth, solid ROE expansion and returning a substantial amount of capital to investors. However, most of the shortfall in core results in Q2 driven by adverse mortality, which should be temporary in nature, said Dally. He trimmed his price target on Voya shares to $64 from $66 but keeps an Overweight rating on the stock.
09/12/19
GSCO
09/12/19
DOWNGRADE
Target $99
GSCO
Buy
Prudential downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Alex Scott removed Prudential Financial (PRU) from his firm's Americas Conviction List while maintaining a Buy rating on the shares. The analyst also lowered his price target for the stock to $99 from $107. Voya Financial (VOYA) has a better ability to beat earnings estimates in the near term as well as in 2020 and 2021 relative to Prudential, Scott tells investors in a research note. While a good amount "near-term negativity" is already priced into Prudential, the shares do not have many catalysts in the next six months outside of earnings beats, adds the analyst. He sees a more challenging near-term setup for Prudential and shifts his conviction to Voya.
09/12/19
GSCO
09/12/19
UPGRADE
Target $68
GSCO
Conviction Buy
Voya Financial upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Alex Scott added Voya Financial (VOYA) to his firm's Americas Conviction List while maintaining a Buy rating on the shares. He also raised his price target for the shares to $68 from $59. Voya has a better ability to beat earnings estimates in the near term as well as in 2020 and 2021 relative to Prudential Financial (PRU), Scott tells investors in a research note. He believes expense reduction, share count reduction, and the addition of a large record keeping contract earn in can drive the upside for Voya.
ABBV AbbVie
$70.37

0.72 (1.03%)

09/04/19
PIPR
09/04/19
NO CHANGE
Target $81
PIPR
Overweight
Dermatologist survey positive for AbbVie's Skyrizi, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says a new survey of 98 dermatologists fielded by his firm's partners Spherix Global Insights indicates that not only is AbbVie's strong initial Q2 Skyrizi print "the real deal," management's guidance of $250M for fiscal 2019 may prove conservative. As of the end of Q2, doctors indicated Skyrizi share was about 1% of patients under management but by year-end 2019, that number should growth to 8%, Raymond tells investors in a research note. The analyst increased his fiscal 2019 and 2020 estimates for Skyrizi and boosted his price target for AbbVie shares to $81 from $80. He remains a buyer of the stock with an Overweight rating, believing upside from both Skyrizi and newly approved Rinvoq to help change the narrative on AbbVie.
08/20/19
08/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pilgrim's Pride (PPC) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow citing the management's implementation of a "successful execution" of its chicken strategy. 2. Beyond Meat (BYND) upgraded to Overweight from Neutral at JPMorgan while Campbell Soup (CPB) was upgraded to Neutral from Underweight. 3. Chemours (CC) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson saying he thinks end-user destocking of TiO2 appears to have run its course and he views the company as the prime beneficiary of an upturn in industry volumes in 2020. 4. AbbVie (ABBV) upgraded to Overweight from Neutral at Piper Jaffray with analyst Christopher Raymond saying while he remains negative on the company's decision to acquire Allergan (AGN), he believes that a bottom on the stock has been found around $66. 5. CACI (CACI) upgraded to Outperform from Neutral at Credit Suisse with analyst Robert Spingarn saying in an uncertain macro environment, he likes a defensive name that can support a multi-year story of organic growth, margin expansion, and M&A optionality, all while offering an attractive valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/19
UBSW
09/12/19
UPGRADE
Target $79
UBSW
Buy
AbbVie upgraded to Buy from Neutral at UBS
UBS analyst Navin Jacob upgraded AbbVie to Buy but lowered his price target to $79 from $85. The analyst sees the company's acquisition of Allegan as "highly compelling", with NewCo generating over $20B of annual free cash flow and a 9% yield by 2023 when its Humira exclusivity patent expires. After 2023, Jacob expects AbbVie's cash flows to remain stable thanks to the company's key growth assets and Allergan's Aesthetics franchise.
09/12/19
UBSW
09/12/19
NO CHANGE
Target $189
UBSW
Buy
Allergan price target raised to $189 from $172 at UBS
UBS analyst Navin Jacob, who this morning upgraded AbbVie (ABBV) to Buy from Neutral, raised his price target on Allergan (AGN) shares to $189 from $172 based on the two companies' deal terms and his revised AbbVie price target of $79. He expects the AbbVie deal to close in the first quarter of 2020, stating that he believes the two have sufficiently addressed possible anti-trust issues with the divestitures of Zenpep and Creon. Jacob keeps a Buy rating on Allergan shares.
KAMN Kaman
$64.01

1.88 (3.03%)

09/12/19
09/12/19
UPGRADE
Target $72

Overweight
Kaman upgraded to Overweight at KeyBanc
As previously reported, KeyBanc analyst Steve Barger upgraded Kaman to Overweight from Sector Weight with a price target of $72 following meetings with management. The analyst believes Kaman will take a disciplined approach in deploying its substantial cash balance toward acquiring highly engineered products in attractive end markets, primarily aerospace. He also expects targets to be accretive to margin, EPS, and free cash flow, which should support or expand Kaman's valuation multiple.
09/12/19
KEYB
09/12/19
UPGRADE
Target $72
KEYB
Overweight
Kaman upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Steve Barger upgraded Kaman to Overweight from Sector Weight with a price target of $72.
12/14/18
12/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) downgraded to Sell from Neutral at Goldman Sachs with analyst Robert Jones saying he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." 2. Cisco (CSCO) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying strengthening information technology spending, an innovation-led refresh cycle, and a rising software mix have lifted Cisco's multiple and its shares to post-recession highs. 3. Universal Health (UHS) downgraded to Sell from Neutral at Goldman Sachs with analyst Stephen Tanal saying a "healthy" macro environment helps acute hospitals' commercial mix, but behavioral health providers like Universal Health over-index to Medicaid and Medicare, "leaving them less exposed to the supportive backdrop." 4. Beacon Roofing (BECN) downgraded to Neutral from Outperform at Wedbush with analyst Jay McCanless saying that yesterday's investor day did not provide any new catalysts to raise EPS estimates or price target. 5. Kaman (KAMN) downgraded to Underweight from Neutral at JPMorgan with analyst Seth Seifman saying he values the stock at 14 times his 2020 earnings per share estimate of $4.05 while adding 15c for potentially accretive M&A, given the company's balance sheet capacity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/19
KEYB
04/17/19
NO CHANGE
KEYB
Ametek, ITT among top potential acquirers in industrial space, says KeyBanc
KeyBanc analysts Jeff Hammond and Steve Barger think moderating organic growth expectations in 2019 due to tough year over year comps may drive industrials to increasingly look toward inorganic avenues for market outgrowth, or to potentially divest businesses to right-size portfolios. The analysts view Ametek (AME), ITT (ITT), Graco (GGG), and Timken (TKR) as the top potential acquirers, and think Actuant (ATU), Colfax (CFX), Eaton (ETN), Kaman (KAMN), NN, Inc. (NNBR), and Milacron (MCRN) could benefit most from a strategic divestiture.

TODAY'S FREE FLY STORIES

INSW

International Seaways

$25.60

-0.28 (-1.08%)

10:29
10/15/19
10/15
10:29
10/15/19
10:29
Conference/Events
International Seaways management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 22

    Oct

AXL

American Axle

$8.03

0.165 (2.10%)

10:25
10/15/19
10/15
10:25
10/15/19
10:25
Options
American Axle call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNS

WNS Holdings

$59.25

-0.77 (-1.28%)

10:25
10/15/19
10/15
10:25
10/15/19
10:25
Conference/Events
WNS Holdings management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 11

    Nov

C

Citi

$70.26

-0.02 (-0.03%)

10:23
10/15/19
10/15
10:23
10/15/19
10:23
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi says accrual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.29

0.01 (0.01%)

10:22
10/15/19
10/15
10:22
10/15/19
10:22
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi now sees net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.29

0.01 (0.01%)

10:22
10/15/19
10/15
10:22
10/15/19
10:22
Hot Stocks
Citi sees expenses down sequentially in Q4, 'solid' pre-tax earnings growth »

For Q4 in ICG, Citi sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.27

-0.01 (-0.01%)

10:20
10/15/19
10/15
10:20
10/15/19
10:20
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sttill sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

IHRT

iHeartMedia

$14.51

-0.49 (-3.27%)

, SFIX

Stitch Fix

$21.01

-0.2 (-0.94%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

IHRT

iHeartMedia

$14.51

-0.49 (-3.27%)

SFIX

Stitch Fix

$21.01

-0.2 (-0.94%)

EHTH

eHealth

$55.75

2.63 (4.95%)

DS

Drive Shack

$4.01

0.28 (7.51%)

AMRN

Amarin

$15.56

0.12 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 07

    Nov

  • 14

    Nov

  • 28

    Dec

BLMN

Bloomin' Brands

$17.27

-0.88 (-4.85%)

, ENB

Enbridge

$35.53

-0.08 (-0.22%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

BLMN

Bloomin' Brands

$17.27

-0.88 (-4.85%)

ENB

Enbridge

$35.53

-0.08 (-0.22%)

TGE

Tallgrass Energy

$19.35

-0.03 (-0.15%)

TEX

Terex

$24.98

-0.13 (-0.52%)

ATI

Allegheny Technologies

$20.15

-0.55 (-2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

  • 08

    Nov

BBBY

Bed Bath & Beyond

$12.26

-0.03 (-0.24%)

, LOW

Lowe's

$111.39

0.725 (0.66%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

BBBY

Bed Bath & Beyond

$12.26

-0.03 (-0.24%)

LOW

Lowe's

$111.39

0.725 (0.66%)

PINC

Premier

$31.20

0.78 (2.56%)

ZEAL

Zealand Pharma

$27.53

4.28 (18.41%)

IMO

Imperial Oil

$24.41

0.165 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

C

Citi

$70.17

-0.11 (-0.16%)

10:18
10/15/19
10/15
10:18
10/15/19
10:18
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sees pre-tax loss of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/15/19
10/15
10:17
10/15/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMBA

Ambarella

$54.38

1.27 (2.39%)

10:16
10/15/19
10/15
10:16
10/15/19
10:16
Recommendations
Ambarella analyst commentary  »

Ambarella ability to ship…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/15/19
10/15
10:16
10/15/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZM

Zoom Video

$70.27

-0.56 (-0.79%)

, PINS

Pinterest

$24.76

-1.215 (-4.68%)

10:11
10/15/19
10/15
10:11
10/15/19
10:11
Hot Stocks
Zoom Video, Pinterest slip as lock-ups for IPOs expire »

Shares of both Zoom Video…

ZM

Zoom Video

$70.27

-0.56 (-0.79%)

PINS

Pinterest

$24.76

-1.215 (-4.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

  • 31

    Oct

  • 19

    Nov

  • 16

    Dec

C

Citi

$69.93

-0.35 (-0.50%)

10:11
10/15/19
10/15
10:11
10/15/19
10:11
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi CFO says to expand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

KNX

Knight-Swift

$35.47

-0.575 (-1.60%)

10:08
10/15/19
10/15
10:08
10/15/19
10:08
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift guidance cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

C

Citi

$69.90

-0.38 (-0.54%)

10:07
10/15/19
10/15
10:07
10/15/19
10:07
Hot Stocks
Citi says environment is 'highly unpredictable,' waters 'choppy' »

CEO Mike Corbat says the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

10:07
10/15/19
10/15
10:07
10/15/19
10:07
Conference/Events
JPMorgan agricultural/machinery analyst holds analyst/industry conference call »

Machinery Equity Analyst…

TLRY

Tilray

$22.00

1.35 (6.54%)

10:05
10/15/19
10/15
10:05
10/15/19
10:05
Options
Tilray call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TNDM

TNDM

, ABT

Abbott

$81.63

1.82 (2.28%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Recommendations
TNDM, Abbott, DexCom analyst commentary  »

Tandem, Abbott agreement…

TNDM

TNDM

ABT

Abbott

$81.63

1.82 (2.28%)

DXCM

DexCom

$147.49

-12.71 (-7.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 04

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

GM

General Motors

$35.28

-0.23 (-0.65%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Periodicals
Breaking Periodicals news story on General Motors »

GM near agreement with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

UNH

UnitedHealth

$233.77

13.45 (6.10%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Hot Stocks
UnitedHealth rises 5.9% »

UnitedHealth is up 5.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

DS

Drive Shack

$4.01

0.28 (7.51%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Hot Stocks
Drive Shack rises 7.0% »

Drive Shack is up 7.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.26

0.93 (21.48%)

10:00
10/15/19
10/15
10:00
10/15/19
10:00
Hot Stocks
Aphria rises 20.9% »

Aphria is up 20.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.